Repligen Corp. Stock
Repligen Corp. Stock
A loss of -1.320% shows a downward development for Repligen Corp..
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
As a result the target price of 144 € shows a positive potential of 38.33% compared to the current price of 104.1 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -1.320% | 5.152% | 3.274% | 0.434% | -26.092% | -33.355% | -28.796% |
| Opko Health Inc. | 3.330% | 11.321% | 31.111% | 0.648% | 8.237% | -9.523% | -60.875% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -0.600% | 0.000% | -5.618% | -13.402% | -14.286% | -42.069% | -31.148% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | 0.000% | 0.000% | -8.333% | 0.917% | -50.000% | -56.863% |
Comments
Repligen (RGEN) had its price target lowered by HSBC Holdings plc from $170.00 to $150.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its "outperform" rating reaffirmed by Wolfe Research. They now have a $145.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by JPMorgan Chase & Co. from $180.00 to $165.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat